POEMS Syndrome Treatment With Lenalidomide (POEMS)
Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.
Sponsor: Celgene Corporation
Listed as NCT01639898, this PHASE2 trial focuses on POEMS Syndrome and remains completed. Sponsored by Celgene Corporation, it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jun 2018 — Aug 2019 [monthly]
Unknown Status PHASE2
▶ Show 2 earlier versions
-
Aug 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2017 — Aug 2017 [monthly]
Recruiting PHASE2
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene Corporation
- Ministry of Health, France
- University Hospital, Limoges
For direct contact, visit the study record on ClinicalTrials.gov .